Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:36:21.724Z.
Consensus retrieved: 2026-10-06T11:12:22.347Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:36:21.724Z.
Quote observation: 2026-10-06T17:34:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 869772d5b15fe2f366f7470de3318cdd420f1d22994776f46b79eb6f67ec6a89
FORWARD PE RATIO
N/A
Eupraxia Pharmaceuticals Inc.
Market Cap
$262.65M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | $262.65M | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $264.03M | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $262.09M | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.00M | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $266.93M | N/A |
| Scribe Therapeutics Inc. (SCTX)vs › | $267.73M | N/A |
| Palisade Bio, Inc. (PALI)vs › | $260.11M | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $268.67M | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $269.16M | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $269.75M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
Consensus estimates for this stock are reported in USD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
